drugset / Trial / NCT06128733

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733

Phase 1/2 Completed 1215 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.

Timeline

Start
2023-10-31
Primary completion
2025-08-27
Completion
2025-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine Intramuscular
Subject MenACYW conjugate vaccine Vaccine Intramuscular
Subject Menveo Vaccine Intramuscular
Subject PENBRAYATM Unknown Intramuscular
Subject Pentavalent Meningococcal ABCYW vaccine Vaccine Intramuscular
Subject Trumenba Vaccine Intramuscular